Sartorius Stedim Biotech S.A. offers a comprehensive portfolio of products and services that support the bioprocessing continuum, from cell line development to commercial manufacturing. Its key offerings include single-use bioreactors, cell culture media, filtration and purification systems, and fluid management solutions. The company's technologies are utilized in the production of monoclonal antibodies, vaccines, and advanced cell and gene therapies. Formed through the 2007 merger of Sartorius AG's biotechnology division and the French company Stedim S.A., it operates globally with a strong presence in North America, Europe, and Asia. Sartorius AG holds a majority stake in the company, which functions as the parent corporation for the group's bioprocessing business.
